Equities

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.51
  • Today's Change-0.46 / -2.09%
  • Shares traded845.33k
  • 1 Year change-20.22%
  • Beta0.8501
Data delayed at least 15 minutes, as of Nov 12 2024 21:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform8
Hold5
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Arrowhead Pharmaceuticals Inc have a median target of 50.50, with a high estimate of 71.00 and a low estimate of 20.00. The median estimate represents a 134.77% increase from the last price of 21.51.
High230.1%71.00
Med134.8%50.50
Low-7.0%20.00

Earnings history & estimates in USD

On Aug 08, 2024, Arrowhead Pharmaceuticals Inc reported 3rd quarter 2024 losses of -1.38 per share.
The next earnings announcement is expected on Nov 26, 2024.
Average growth rate-11.34%
Arrowhead Pharmaceuticals Inc reported annual 2023 losses of -1.92 per share on Nov 29, 2023.
Average growth rate-33.22%
More ▼

Revenue history & estimates in USD

Arrowhead Pharmaceuticals, Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 62.55m.
Average growth rate-44.06%
Arrowhead Pharmaceuticals, Inc. had revenues for the full year 2023 of 240.74m. This was 1.03% below the prior year's results.
Average growth rate+21.04%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.